IL-22 Reporter HEK 293 Cells
HEK-Blue™ IL-22 Cells | Unit size | Cat. code | Docs | Qty | Price |
---|---|---|---|---|---|
Human & Mouse IL-22 Reporter Cells |
3-7 x 10e6 cells |
hkb-il22 |
You may also need : QUANTI-Blue™ | View more associated products ▼
IL-22 Reporter Cells
HEK-Blue™ IL-22 Cells signaling pathway
HEK-Blue™ IL-22 cells were engineered from the human embryonic kidney HEK293 cell line to detect bioactive human and murine IL-22 by monitoring the activation of the STAT3 pathway. These cells can also be used for screening anti-IL-22 antibodies.
Interleukin 22 (IL-22) is a key regulator of immunity and inflammation at mucosal surfaces where it helps in maintaining barrier integrity [1-3].
Cell line description:
HEK-Blue™ IL-22 cells were generated by stable transfection of HEK293 cells with the human genes for IL-22 receptor (IL-22R1 and IL-10Rβ), STAT3, and a STAT3-inducible SEAP (secreted embryonic alkaline phosphatase) reporter. Binding of IL-22 to its receptor on the surface of HEK-Blue™ IL-22 cells triggers a signaling cascade leading to the activation of STAT3, and the subsequent production of SEAP. For your convenience, InvivoGen provides QUANTI‑Blue™ Solution, an easy and rapid means to detect and quantify SEAP activity in the cell culture supernatant.
Features of HEK-Blue™ IL-22 cells:
- Fully functional IL-22 signaling pathway
- Readily assessable SEAP reporter activity
- Functionally tested
- Guaranteed mycoplasma-free
Applications of HEK-Blue™ IL-22 cells:
- Detection of both human and murine IL-22
- Screening of anti-IL-22 antibodies
References:
1. Wang J.et al., 2018. Aryl hydrocarbon receptor/IL-22/Stat3 signaling pathway is involved in the modulation of intestinal mucosa antimicrobial molecules by commensal microbiota in mice. Innate Immun. 24(5):297-306.
2. Foxall R.B. et al.., 2016. Profile of interleukin-22 in gut mucosal health and disease. IJICMR. 8:1-11.
3. Park J.H. et al., 2017. There Is a Gap in Our Knowledge. Immunohorizons. 2(6):198-207.
Specifications
Antibiotic resistance: Blasticidin, Puromycin, Zeocin®
Growth medium: DMEM, 4.5 g/l glucose, 2-4 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml Normocin™
Guaranteed mycoplasma-free
Specificity: human and mouse IL-22
Detection range:
- 0.03 - 10 ng/ml for human IL-22
- 0.1 - 10 ng/ml for murine IL-22
These cells are covered by a Limited Use License (See Terms and Conditions).
Back to the topContents
- 1 vial containing 3-7 x 106 cells
- 1 ml of Blasticidin (10 mg/ml)
- 1 ml of Puromycin (10 mg/ml)
- 1 ml of Zeocin® (100 mg/ml)
- 1 ml of Normocin™ (50 mg/ml)
- 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent)
Shipped on dry ice (Europe, USA, Canada and some areas in Asia)
Details
Interleukin 22 (IL-22) is a key regulator of immunity and inflammation at mucosal surfaces where it helps in maintaining barrier integrity [1-3]. IL-22 production can be triggered by a variety of pathogen-associated molecular patterns (PAMPs). Notably, it can be induced directly by Toll-like receptor 2 (TLR2) activation in response to bacterial-derived agonists, or indirectly via IL-23 in response to aryl-hydrocarbon receptor (AhR) ligands [1, 2]. IL-22 is implicated in a number of pathologies including autoimmune diseases and cancer [3, 4].
IL-22 exerts its biological effect upon binding to its receptor, which comprises two subunits: IL-22R1 and IL-10Rβ. Upon binding, IL-22 triggers a signaling pathway involving tyrosine kinase 2 (TyK2) and Janus kinase 1 (JAK1) leading to the activation of signal transducer and activator of transcription 3 (STAT3).
1. Wang J.et al., 2018. Aryl hydrocarbon receptor/IL-22/Stat3 signaling pathway is involved in the modulation of intestinal mucosa antimicrobial molecules by commensal microbiota in mice. Innate Immun. 24(5):297-306.
2. Foxall R.B. et al.., 2016. Profile of interleukin-22 in gut mucosal health and disease. IJICMR. 8:1-11.
3. Park J.H. et al., 2017. There Is a Gap in Our Knowledge. Immunohorizons. 2(6):198-207.
4. Hernandez P. et al., 2018. A catch-22: Interleukin-22 and cancer. Eur J Immunol. 48(1):15-31.